Ovarian Cancer

The FDA has granted accelerated approval to avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ovarian cancer.

A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.

Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis of the phase 3 ARTISTRY-7 trial.

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, but not longer, follow-ups.

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.

A combination of avutometinib and defactinib has been granted priority review by the FDA for the treatment of KRAS-mutant recurrent low-grade serous ovarian cancer.

Niraparib plus dostarlimab with platinum-based chemotherapy achieved superior PFS, meeting the primary end point of the phase 3 FIRST-ENGOT-OV44 trial.

PARP inhibitors have changed the way we think about [managing] ovarian cancer,” Whitney Goldsberry, MD, said

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

The FDA has received a rolling new drug application (NDA) for avutometinib plus defactinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer harboring KRAS mutations who have received at least 1 prior line of systemic therapy.

Adding IMNN-001 to perioperative chemotherapy enhanced overall survival in patients with newly diagnosed, advanced ovarian cancer.

Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.

Alpha-emitting radiopharmaceutical Radspherin receives a fast track designation from the FDA for peritoneal carcinomatosis from ovarian cancer.

An oncology nurse's experience with her mother's cancer and her own BRCA2 diagnosis shapes her approach to patient care.

A durvalumab-based combination followed by an olaparib-based maintenance therapy improved progression-free survival in newly diagnosed advanced ovarian cancer without BRCA1/2 mutations.

Progression-free survival and platinum chemoresistance may be predicted by tumor-stroma proportion in patients with high-grade serous ovarian cancer.

The ready-to-dilute formulation of Tepylute for breast and ovarian cancers can help to reduce prep time and provide more accurate dosing.

Compared with placebo, first-line rucaparib maintenance therapy maintained a PFS benefit at 4 years in newly diagnosed advanced ovarian cancer.

Patients with recurrent ovarian cancer did not derive a benefit from adding atezolizumab to chemotherapy and bevacizumab.

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Postmenopausal women who had undergone hysterectomy and received treatment with conjugated equine estrogen alone had an increased incidence of ovarian cancer and mortality rates.

Patients with platinum-resistant or -refractory epithelial ovarian cancer treated with olaparib plus cediranib did not experience improvements in PFS and OS compared with chemotherapy.

Further evidence strengthens the support of mirvetuximab soravtansine as a new standard of care for folate receptor-alpha—positive ovarian cancer resistant to platinum chemotherapy.